Excellence in clinical research from A to Z

Scroll down ⇩

About us

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO) located in Overath near Cologne, Germany, with over 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.


From its head office located in Overath, Germany, AtoZ-CRO manages and coordinates clinical studies of phase 0 through phase IV for national and international clients. The company forms a team of 35 highly experienced and dedicated industry professionals and medical specialists ensuring high standards in clinical study management. AtoZ-CRO is affiliated with a leading initiator of phase I studies in Warsaw, Poland.


Based on the company’s long-established international experience in clinical trial management and cooperation with high-rated business partners, AtoZ-CRO is proud to offer a broad range of services covering all clinical research needs, in particular for small and mid-sized pharmaceutical, biotech, and medical device companies.

Clinical Studies 

Contact us

Clinical Studies

Clinical Studies Phases 0 – IV

  • Planning of clinical studies
  • Preparation of study protocols
  • Design and implementation of CRFs (case report forms) and eCRFs
  • Processing of applications for ethical votes and permissions (e.g. CTA, IND)
  • Regulatory affairs issues
  • Legal EU representative

Other services

  • Monitoring
  • Post-marketing studies

-  NIS

-  PASS

-  Epidemiology

  • Pharmacovigilance
  • Biometry
  • Medical Writing and Translations

About us

Contact us

Contact us

AtoZ-CRO GmbH

Hauptstr. 77
51491 Overath
Tel: 02206 95 99 0
Fax: 02206 820 63
Email: info@atoz-cro.de
www.atoz-cro.de

Business Development

Alexa Foltin-Mertgen, M.Sc.
Email: a.foltin-mertgen@atoz-cro.de

Back to top ⇧

Go to article: Home | The dengue dilemma Go to article: In this issueGo to article: Owen MumfordGo to article: ContentsGo to article: Hapa Company Insight Go to article: Daiichi JitsugyoGo to article: NewsGo to article: EmbocapsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: The pharma industry briefingGo to article: Dow Europe Company InsightGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The problem of manipulated data Go to article: Capsugel Company Insight Go to article: CapsugelGo to article: Timeline: the dengue vaccine dilemmaGo to article: TSS Company Insight Go to article: TSSGo to article: From evergreening to thicketing: exploring manipulation of the pharma patent sysGo to article: Emirates SkyCargoGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Swiss WorldCargoGo to article: Accurate BiometricsGo to article: Accurate Biometrics Company Insight Go to article: Nelson LabsGo to article: Treading the line: the challenge of transplant rejection drugsGo to article: Corbion PuracGo to article: Erdmann Design Company InsightGo to article: Erdmann Design SwitzerlandGo to article: Treating menopause: at last a non-hormonal alternative? Go to article: YourwayGo to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Drug repurposing: the industry’s all-rounder medicinesGo to article: FargoGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: One step closer to a Chlamydia vaccine Go to article: AralabGo to article: Synex SyntheticsGo to article: Deals in brief powered by GlobalDataGo to article: Charles Ischi Go to article: The key list powered by GlobalDataGo to article: Pharmaceutical Solutions IndustryGo to article: Clinichain Company Insight Go to article: ClinichainGo to article: SanofiGo to article: EventsGo to article: NymiGo to article: Modality SolutionsGo to article: PfanstiehlGo to article: Next issueGo to article: MimotopesGo to article: ICCI - International Cannabis and Cannabinoids Institute Go to article: ICCI